Suven Pharmaceuticals Limited
NSE:SUVENPHAR.NS
1076.9 (INR) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 472.312 | 648.028 | 445.638 | 71.822 | 116.953 | 109.03 |
| Short Term Investments
| 7,738.955 | 4,224.279 | 4,812.224 | 1,805.938 | 306.761 | 70.638 |
| Cash and Short Term Investments
| 8,211.267 | 4,872.307 | 5,257.862 | 1,877.76 | 423.714 | 179.668 |
| Net Receivables
| 1,336.592 | 1,109.393 | 2,363.723 | 1,023.821 | 1,171.958 | 1,475.017 |
| Inventory
| 2,311.956 | 3,128.105 | 2,834.173 | 2,010.804 | 1,748.723 | 1,570.982 |
| Other Current Assets
| 758.135 | 857.921 | 657.568 | 619.079 | 457.701 | 617.732 |
| Total Current Assets
| 12,631.863 | 10,110.458 | 11,279.32 | 5,647.852 | 3,916.467 | 3,897.342 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 7,867.76 | 7,662.249 | 5,619.513 | 5,348.896 | 4,556.53 | 3,792.808 |
| Goodwill
| 602.583 | 602.583 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 16.674 | 621.902 | 22.364 | 25.904 | 27.96 | 26.851 |
| Goodwill and Intangible Assets
| 619.257 | 621.902 | 22.364 | 25.904 | 27.96 | 26.851 |
| Long Term Investments
| 1,305.819 | 1,170.966 | 1,170.966 | 3,611.941 | 3,074.581 | 0.705 |
| Tax Assets
| 0 | 59.344 | 203.711 | 50.137 | 19.439 | 0 |
| Other Non-Current Assets
| 116.166 | 32.519 | -0.001 | 59.921 | 133.128 | -3,820.364 |
| Total Non-Current Assets
| 9,909.002 | 9,546.98 | 7,016.553 | 9,096.799 | 7,811.638 | 3,932.821 |
| Total Assets
| 22,540.865 | 19,657.438 | 18,295.873 | 14,744.651 | 11,728.105 | 7,830.163 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 423.574 | 487.718 | 1,059.005 | 725.909 | 710.557 | 535.749 |
| Short Term Debt
| 437.608 | 650.768 | 682.24 | 1,067.058 | 944.421 | 668.245 |
| Tax Payables
| 0 | 2.939 | 36.422 | 0 | 52.536 | 1.096 |
| Deferred Revenue
| 1.582 | 255.72 | 340.704 | 278.545 | 309.653 | 159.691 |
| Other Current Liabilities
| 206.193 | 438.156 | 287.271 | 404.441 | 284.223 | 51.615 |
| Total Current Liabilities
| 1,068.957 | 1,587.658 | 2,102.94 | 2,197.48 | 2,003.715 | 1,576.087 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 212.356 | 52.64 | 289.033 | 363.299 | 917.644 | 0 |
| Deferred Revenue Non-Current
| 0 | 128.593 | 373.349 | 422.369 | 83.146 | 0 |
| Deferred Tax Liabilities Non-Current
| 647.912 | 582.346 | 543.151 | 309.329 | 275.972 | 291.717 |
| Other Non-Current Liabilities
| 105.005 | 665.297 | 632.096 | 375.789 | 0.001 | 59.453 |
| Total Non-Current Liabilities
| 965.273 | 717.937 | 921.129 | 739.088 | 1,276.763 | 351.17 |
| Total Liabilities
| 2,034.23 | 2,305.595 | 3,024.069 | 2,936.568 | 3,280.478 | 1,927.257 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 254.565 | 254.565 | 254.565 | 254.565 | 127.282 | 127.282 |
| Retained Earnings
| 17,651.18 | 14,651.606 | 12,727.086 | 9,364.926 | 6,154.443 | 3,909.835 |
| Accumulated Other Comprehensive Income/Loss
| 1,505.152 | 1,349.934 | 1,194.414 | 1,092.854 | 942.88 | 642.767 |
| Other Total Stockholders Equity
| 1,095.738 | 1,095.738 | 1,095.738 | 1,095.738 | 2,015.787 | 1,223.021 |
| Total Shareholders Equity
| 20,506.635 | 17,351.843 | 15,271.803 | 11,808.083 | 8,447.627 | 5,902.905 |
| Total Equity
| 20,506.635 | 17,351.843 | 15,271.803 | 11,808.083 | 8,447.627 | 5,902.905 |
| Total Liabilities & Shareholders Equity
| 22,540.865 | 19,657.438 | 18,295.872 | 14,744.651 | 11,728.105 | 7,830.162 |